Insulin-like growth factor-I inhibits growth regulatory responses engaged by estrogen and progesterone in the mouse mammary gland

European Journal of Cancer Prevention

Volumn 17, Issue 4, 2008, Pages 297-305

  Mathews, Lesley ^a   Schneider, Sallie Smith ^a,b,c  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

^b Pioneer Valley Life Sciences Institute   (United States)

^c BAYSTATE MEDICAL CENTER   (United States)

Author keywords

Cellular retinol binding protein 1; Insulin growth factor i; P53; Parity; Transforming growth factor b 1

Indexed keywords

CELLULAR RETINOL BINDING PROTEIN 1; ESTROGEN; PROGESTERONE; PROTEIN P21; PROTEIN P53; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DNA DAMAGE; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME REGULATION; FEMALE; IN VITRO STUDY; MAMMARY GLAND; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; CELL CULTURE; DISEASE MODEL; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; NICK END LABELING; ORGAN CULTURE TECHNIQUE; PATHOLOGY; PHYSIOLOGY; RANDOMIZATION; REFERENCE VALUE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; UDDER;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MAMMARY GLANDS, ANIMAL; MICE; MICE, INBRED BALB C; ORGAN CULTURE TECHNIQUES; PROGESTERONE; RANDOM ALLOCATION; REFERENCE VALUES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TRANSFORMING GROWTH FACTOR BETA1;

EID: 49649127691     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/CEJ.0b013e3282f521ce     Document Type: Article

References (48)

1. Adamo ML, Shao ZM, Lanau F, Chen JC, Clemmons DR, Roberts CT Jr, et al. (1992). Insulin-like growth factor-I (IGF-I) and retinoic acid modulation of IGF- binding proteins (IGFBPs): IGFBP-2, -3, and -4 gene expression and protein secretion in a breast cancer cell line. Endocrinology 131:1858-1866.
2. Allen NE, Roddam AW, Allen DS, Fentiman IS, Dos Santos Silva I, Peto J, et al. (2005). A prospective study of serum insulin-like growth factor-I (IGF-I), IGF-II, IGF-binding protein-3 and breast cancer risk. Br J Cancer 92: 1283-1287.
3. Baserga R, Hongo A, Rubini M, Prisco M, Valentinis B (1997). The IGF-I receptor in cell growth, transformation and apoptosis. Biochim Biophys Acta 1332:F105-F126.
4. Becker KA, Lu S, Dickinson ES, Dunphy KA, Mathews L, Schneider SS, Jerry DJ (2005). Estrogen and progesterone regulate radiation-induced p53 activity in mammary epithelium through TGF-beta-dependent pathways. Oncogene 24:6345-6353.
5. Bernstein L (2002). Epidemiology of endocrine-related risk factors for breast cancer. J Mammary Gland Biol Neoplasia 7:3-15.
6. Blackburn AC, Jerry DJ (2002). Knockout and transgenic mice of Trp53: what have we learned about p53 in breast cancer? Breast Cancer Res 4: 101-111.
7. Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B, Seizinger BR, Kley N (1995). Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377:646-649.
8. D'Cruz CM, Moody SE, Master SR, Hartman JL, Keiper EA, Imielinski MB, et al. (2002). Persistent parity-induced changes in growth factors, TGF-beta3, and differentiation in the rodent mammary gland. Mol Endocrinol 16:2034-2051.
9. Ewan KB, Henshall-Powell RL, Ravani SA, Pajares MJ, Arteaga C, Warters R, et al. (2002a). Transforming growth factor-beta1 mediates cellular response to DNA damage in situ. Cancer Res 62:5627-5631.
10. Ewan KB, Shyamala G, Ravani SA, Tang Y, Akhurst R, Wakefield L, Barcellos-Hoff MH (2002b). Latent transforming growth factor-beta activation in mammary gland: regulation by ovarian hormones affects ductal and alveolar proliferation. Am J Pathol 160:2081-2093.
11. Firth SM, Baxter RC (2002). Cellular actions of the insulin-like growth factor binding protein. Endocr Rev 23:824-854.
12. Giovannucci E (1999). Insulin-like growth factor-I and binding protein-3 and risk of cancer. Horm Res 51 (Suppl 3):34-41.
13. Grimberg A, Liu B, Bannerman P, El-Deiry WS, Cohen P (2002). IGFBP-3 mediates p53-induced apoptosis during serum starvation. Int J Oncol 21:327-335.
14. Hadsell DL, Greenberg NM, Fligger JM, Baumrucker CR, Rosen JM (1996). Targeted expression of des (1-3) human insulin-like growth factor I in transgenic mice influences mammary gland development and IGF-binding protein expression. Endocrinology 137:321-330.
15. Hadsell DL, Alexeenko T, Klimentidis Y, Torres D, Lee AV (2001). Inability of overexpressed des (1-3) human insulin-like growth factor I (IGF-I) to inhibit forced mammary gland involution is associated with decreased expression of IGF signaling molecules. Endocrinology 142:1479- 1488.
16. Helle SI, Ekse D, Holly JM, Lonning PE (2002). The IGF-system in healthy preand postmenopausal women: relations to demographic variables and sexsteroids. J Steroid Biochem Mol Biol 81:95-102.
17. Heron-Milhavet L, Karas M, Goldsmith CM, Baum BJ, LeRoith D (2001). Insulinlike growth factor-I (IGF-I) receptor activation rescues UV-damaged cells through a p38 signaling pathway. Potential role of the IGF-I receptor in DNA repair. J Biol Chem 276:18185-18192.
18. Hollowood AD, Stewart CE, Perks CM, Pell JM, Lai T, Alderson D, Holly JM (2002). Evidence implicating a mid-region sequence of IGFBP-3 in its specific IGF-independent actions. J Cell Biochem 86:583-589.
19. Huynh H, Beamer W, Pollak M, Chan TW (2000). Modulation of transforming growth factor beta1 gene expression in the mammary gland by insulin-like growth factor I and octreotide. Int J Oncol 16:277-281.
20. Kelsey JL, Gammon MD, John EM (1993). Reproductive factors and breast cancer. Epidemiol Rev 15:36-47.
21. Kuppumbatti YS, Bleiweiss IJ, Mandeli JP, Waxman S, Mira YLR (2000). Cellular retinol-binding protein expression and breast cancer. J Natl Cancer Inst 92:475-480.
22. Kuppumbatti YS, Rexer B, Nakajo S, Nakaya K, Mira-y-Lopez R (2001). CRBP suppresses breast cancer cell survival and anchorage-independent growth. Oncogene 20:7413-7419.
23. LeRoith D, Werner H, Beitner-Johnson D, Roberts CT Jr (1995). Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 16:143-163.
24. Lu S, Becker KA, Hagen MJ, Roberts AL, Smith-Schneider S, Siegelmann HT, et al. (2008). Transcriptional responses to estrogen and progesterone in mammary gland identify networks regulating p53 activity. Endocrinology In Press.
25. MacMahon B, Cole P, Lin TM, Lowe CR, Mirra AP, Ravnihar B, et al. (1970). Age at first birth and breast cancer risk. Bull World Health Organ 43: 209-221.
26. Medina D (2004). Breast cancer: the protective effect of pregnancy. Clin Cancer Res 10 (1 Pt 2):380S-384S.
27. Medina D, Kittrell FS (2003). p53 function is required for hormone-mediated protection of mouse mammary tumorigenesis. Cancer Res 63:6140-6143.
28. Medina D, Sivaraman L, Hilsenbeck SG, Conneely O, Ginger M, Rosen J, Omalle BW (2001). Mechanisms of hormonal prevention of breast cancer. Ann N Y Acad Sci 952:23-35.
29. Minter LM, Dickinson ES, Naber SP, Jerry DJ (2002). Epithelial cell cycling predicts p53 responsiveness to gamma-irradiation during post-natal mammary gland development. Development 129:2997-3008.
30. Neuenschwander S, Schwartz A, Wood TL, Roberts CT Jr, Hennighausen L, LeRoith D (1996). Involution of the lactating mammary gland is inhibited by the IGF system in a transgenic mouse model. J Clin Invest 97:2225-2232.
31. Ohlsson C, Kley N, Werner H, LeRoith D (1998). p53 regulates insulin-like growth factor-I (IGF-I) receptor expression and IGF-I-induced tyrosine phosphorylation in an osteosarcoma cell line: interaction between p53 and Sp1. Endocrinology 139:1101-1107.
32. Pasquali D, Bellastella A, Valente A, Botti G, Capasso I, del Vecchio S, et al. (1997). Retinoic acid receptors alpha, beta and gamma, and cellular retinol binding protein-I expression in breast fibrocystic disease and cancer. Eur J Endocrinol 137:410-414.
33. Rajkumar L, Guzman RC, Yang J, Thordarson G, Talamantes F, Nandi S (2001). Short-term exposure to pregnancy levels of estrogen prevents mammary carcinogenesis. Proc Natl Acad Sci 98:11755-11759.
34. Rinaldi S, Toniolo P, Muti P, Lundin E, Zeleniuch-Jacquotte A, Arslan A, et al. (2005). IGF-I, IGFBP-3 and breast cancer in young women: a pooled reanalysis of three prospective studies. Eur J Cancer Prev 14:493-496.
35. Ruan W, Kleinberg DL (1999). Insulin-like growth factor I is essential for terminal end bud formation and ductal morphogenesis during mammary development. Endocrinology 140:5075-5081.
36. Russo J, Tay LK, Russo IH (1982). Differentiation of the mammary gland and susceptibility to carcinogenesis. Breast Cancer Res Treat 2:5-73.
37. Russo J, Moral R, Balogh GA, Mailo D, Russo IH (2005). The protective role of pregnancy in breast cancer. Breast Cancer Res 7:131-142.
38. Sachdev D, Yee D (2001). The IGF system and breast cancer. Endocr Relat Cancer 8:197-209.
39. Schernhammer ES, Holly JM, Pollak MN, Hankinson SE (2005). Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 14:699-704.
40. Sinha DK, Pazik JE, Dao TL (1988). Prevention of mammary carcinogenesis in rats by pregnancy: effect of full-term and interrupted pregnancy. Br J Cancer 57:390-394.
41. Sivaraman L, Medina D (2002). Hormone-induced protection against breast cancer. J Mammary Gland Biol Neoplasia 7:77-92.
42. Stoll BA (2002). Linkage between retinoid and fatty acid receptors: implications for breast cancer prevention. Eur J Cancer Prev 11:319-325.
43. Swanson SM, Whitaker LM, Stockard CR, Myers RB, Oelschlager D, Grizzle WE, et al. (1997). Hormone levels and mammary epithelial cell proliferation in rats treated with a regimen of estradiol and progesterone that mimics the preventive effect of pregnancy against mammary cancer. Anticancer Res 17:4639-4645.
44. Thordarson G, Slusher N, Leong H, Ochoa D, Rajkumar L, Guzman R, et al. (2004). Insulin-like growth factor (IGF) -I obliterates the pregnancy-associated protection against mammary carcinogenesis in rats: evidence that IGF-I enhances cancer progression through estrogen receptor-alpha activation via the mitogen-activated protein kinase pathway. Breast Cancer Res 6:R423-R436.
45. Tu Y, Jerry DJ, Pazik B, Smith Schneider S (2005). Sensitivity to DNA damage is a common component of hormone-based strategies for protection of the mammary gland. Mol Cancer Res 3:435-442.
46. Vadgama JV, Wu Y, Datta G, Khan H, Chillar R (1999). Plasma insulin-like growth factor-I and serum IGF-binding protein 3 can be associated with the progression of breast cancer, and predict the risk of recurrence and the probability of survival in African-American and Hispanic women. Oncology 57:330-340.
47. Werner H, Karnieli E, Rauscher FJ, LeRoith D (1996). Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc Natl Acad Sci 93:8318-8323.
48. Yang J, Yoshizawa K, Nandi S, Tsubura A (1999). Protective effects of pregnancy and lactation against N-methyl-N-nitrosourea-induced mammary carcinomas in female Lewis rats. Carcinogenesis 20:623-628.